nodes	percent_of_prediction	percent_of_DWPC	metapath
Sirolimus—MTOR—ovarian cancer	0.411	0.853	CbGaD
Sirolimus—ABCB1—ovarian cancer	0.0706	0.147	CbGaD
Sirolimus—CYP3A7—Paclitaxel—ovarian cancer	0.0223	0.109	CbGbCtD
Sirolimus—CYP3A7-CYP3A51P—Paclitaxel—ovarian cancer	0.0223	0.109	CbGbCtD
Sirolimus—ABCB1—Topotecan—ovarian cancer	0.022	0.107	CbGbCtD
Sirolimus—CYP3A5—Paclitaxel—ovarian cancer	0.0167	0.0816	CbGbCtD
Sirolimus—CYP3A7—Docetaxel—ovarian cancer	0.0161	0.0786	CbGbCtD
Sirolimus—CYP3A7-CYP3A51P—Docetaxel—ovarian cancer	0.0161	0.0786	CbGbCtD
Sirolimus—ABCB1—Vinorelbine—ovarian cancer	0.0155	0.0756	CbGbCtD
Sirolimus—CYP3A4—Topotecan—ovarian cancer	0.0132	0.0643	CbGbCtD
Sirolimus—CYP3A5—Docetaxel—ovarian cancer	0.0121	0.059	CbGbCtD
Sirolimus—ABCB1—Paclitaxel—ovarian cancer	0.0109	0.0531	CbGbCtD
Sirolimus—CYP3A4—Vinorelbine—ovarian cancer	0.00929	0.0453	CbGbCtD
Sirolimus—ABCB1—Docetaxel—ovarian cancer	0.00788	0.0384	CbGbCtD
Sirolimus—CYP3A4—Paclitaxel—ovarian cancer	0.00653	0.0318	CbGbCtD
Sirolimus—ABCB1—Doxorubicin—ovarian cancer	0.00587	0.0286	CbGbCtD
Sirolimus—CYP3A4—Docetaxel—ovarian cancer	0.00472	0.023	CbGbCtD
Sirolimus—CYP3A4—Doxorubicin—ovarian cancer	0.00352	0.0171	CbGbCtD
Sirolimus—EIF4E—embryo—ovarian cancer	0.00331	0.0571	CbGeAlD
Sirolimus—EIF4E—uterine cervix—ovarian cancer	0.00268	0.0462	CbGeAlD
Sirolimus—EIF4E—gonad—ovarian cancer	0.00224	0.0388	CbGeAlD
Sirolimus—EIF4E—uterus—ovarian cancer	0.00223	0.0385	CbGeAlD
Sirolimus—FGF2—myometrium—ovarian cancer	0.0021	0.0362	CbGeAlD
Sirolimus—EIF4E—female reproductive system—ovarian cancer	0.002	0.0346	CbGeAlD
Sirolimus—FGF2—uterine cervix—ovarian cancer	0.00163	0.0282	CbGeAlD
Sirolimus—EIF4E—testis—ovarian cancer	0.00162	0.0279	CbGeAlD
Sirolimus—FGF2—decidua—ovarian cancer	0.00155	0.0268	CbGeAlD
Sirolimus—Everolimus—MTOR—ovarian cancer	0.00153	0.287	CrCbGaD
Sirolimus—Pimecrolimus—MTOR—ovarian cancer	0.00153	0.287	CrCbGaD
Sirolimus—FGF2—endometrium—ovarian cancer	0.00148	0.0255	CbGeAlD
Sirolimus—FGF2—uterus—ovarian cancer	0.00136	0.0235	CbGeAlD
Sirolimus—MTOR—myometrium—ovarian cancer	0.00133	0.023	CbGeAlD
Sirolimus—MTOR—embryo—ovarian cancer	0.00128	0.0221	CbGeAlD
Sirolimus—FKBP1A—myometrium—ovarian cancer	0.0012	0.0207	CbGeAlD
Sirolimus—FGF2—female gonad—ovarian cancer	0.00111	0.0192	CbGeAlD
Sirolimus—FGF2—vagina—ovarian cancer	0.00111	0.0191	CbGeAlD
Sirolimus—MTOR—epithelium—ovarian cancer	0.00104	0.018	CbGeAlD
Sirolimus—Temsirolimus—MTOR—ovarian cancer	0.00103	0.194	CrCbGaD
Sirolimus—SLC47A1—myometrium—ovarian cancer	0.00103	0.0178	CbGeAlD
Sirolimus—FGF2—testis—ovarian cancer	0.000987	0.017	CbGeAlD
Sirolimus—FKBP1A—epithelium—ovarian cancer	0.000939	0.0162	CbGeAlD
Sirolimus—MTOR—endometrium—ovarian cancer	0.000936	0.0162	CbGeAlD
Sirolimus—FKBP1A—uterine cervix—ovarian cancer	0.000931	0.0161	CbGeAlD
Sirolimus—Tacrolimus—MTOR—ovarian cancer	0.000908	0.171	CrCbGaD
Sirolimus—FKBP1A—decidua—ovarian cancer	0.000887	0.0153	CbGeAlD
Sirolimus—MTOR—gonad—ovarian cancer	0.000869	0.015	CbGeAlD
Sirolimus—MTOR—uterus—ovarian cancer	0.000863	0.0149	CbGeAlD
Sirolimus—FKBP1A—endometrium—ovarian cancer	0.000842	0.0145	CbGeAlD
Sirolimus—SLC47A1—uterine cervix—ovarian cancer	0.0008	0.0138	CbGeAlD
Sirolimus—FKBP1A—gonad—ovarian cancer	0.000781	0.0135	CbGeAlD
Sirolimus—FKBP1A—uterus—ovarian cancer	0.000776	0.0134	CbGeAlD
Sirolimus—MTOR—female reproductive system—ovarian cancer	0.000776	0.0134	CbGeAlD
Sirolimus—SLC47A1—decidua—ovarian cancer	0.000762	0.0132	CbGeAlD
Sirolimus—MTOR—bone marrow—ovarian cancer	0.000732	0.0126	CbGeAlD
Sirolimus—SLC47A1—endometrium—ovarian cancer	0.000724	0.0125	CbGeAlD
Sirolimus—FGF2—lymph node—ovarian cancer	0.000715	0.0124	CbGeAlD
Sirolimus—MTOR—female gonad—ovarian cancer	0.000706	0.0122	CbGeAlD
Sirolimus—MTOR—vagina—ovarian cancer	0.000702	0.0121	CbGeAlD
Sirolimus—FKBP1A—female reproductive system—ovarian cancer	0.000698	0.012	CbGeAlD
Sirolimus—SLC47A1—gonad—ovarian cancer	0.000671	0.0116	CbGeAlD
Sirolimus—SLC47A1—uterus—ovarian cancer	0.000667	0.0115	CbGeAlD
Sirolimus—FKBP1A—bone marrow—ovarian cancer	0.000659	0.0114	CbGeAlD
Sirolimus—FKBP1A—female gonad—ovarian cancer	0.000635	0.011	CbGeAlD
Sirolimus—FKBP1A—vagina—ovarian cancer	0.000631	0.0109	CbGeAlD
Sirolimus—MTOR—testis—ovarian cancer	0.000626	0.0108	CbGeAlD
Sirolimus—SLC47A1—female reproductive system—ovarian cancer	0.0006	0.0104	CbGeAlD
Sirolimus—SLCO1B1—female reproductive system—ovarian cancer	0.000592	0.0102	CbGeAlD
Sirolimus—FKBP1A—testis—ovarian cancer	0.000563	0.00972	CbGeAlD
Sirolimus—SLC47A1—female gonad—ovarian cancer	0.000546	0.00942	CbGeAlD
Sirolimus—SLC47A1—vagina—ovarian cancer	0.000542	0.00937	CbGeAlD
Sirolimus—SLC47A1—testis—ovarian cancer	0.000484	0.00836	CbGeAlD
Sirolimus—MTOR—lymph node—ovarian cancer	0.000454	0.00784	CbGeAlD
Sirolimus—FKBP1A—lymph node—ovarian cancer	0.000408	0.00705	CbGeAlD
Sirolimus—CYP3A5—uterine cervix—ovarian cancer	0.000405	0.007	CbGeAlD
Sirolimus—SLC47A1—lymph node—ovarian cancer	0.000351	0.00606	CbGeAlD
Sirolimus—ABCB1—myometrium—ovarian cancer	0.000277	0.00478	CbGeAlD
Sirolimus—CYP3A5—female gonad—ovarian cancer	0.000276	0.00477	CbGeAlD
Sirolimus—CYP3A5—vagina—ovarian cancer	0.000275	0.00475	CbGeAlD
Sirolimus—ABCB1—embryo—ovarian cancer	0.000266	0.0046	CbGeAlD
Sirolimus—CYP3A4—female reproductive system—ovarian cancer	0.000228	0.00394	CbGeAlD
Sirolimus—ABCB1—epithelium—ovarian cancer	0.000217	0.00375	CbGeAlD
Sirolimus—ABCB1—uterine cervix—ovarian cancer	0.000215	0.00372	CbGeAlD
Sirolimus—ABCB1—decidua—ovarian cancer	0.000205	0.00354	CbGeAlD
Sirolimus—ABCB1—endometrium—ovarian cancer	0.000195	0.00336	CbGeAlD
Sirolimus—ABCB1—gonad—ovarian cancer	0.000181	0.00312	CbGeAlD
Sirolimus—ABCB1—uterus—ovarian cancer	0.00018	0.0031	CbGeAlD
Sirolimus—Temsirolimus—ABCB1—ovarian cancer	0.000177	0.0333	CrCbGaD
Sirolimus—ABCB1—female reproductive system—ovarian cancer	0.000161	0.00279	CbGeAlD
Sirolimus—Tacrolimus—ABCB1—ovarian cancer	0.000156	0.0293	CrCbGaD
Sirolimus—ABCB1—bone marrow—ovarian cancer	0.000152	0.00263	CbGeAlD
Sirolimus—ABCB1—female gonad—ovarian cancer	0.000147	0.00254	CbGeAlD
Sirolimus—ABCB1—vagina—ovarian cancer	0.000146	0.00252	CbGeAlD
Sirolimus—ABCB1—testis—ovarian cancer	0.00013	0.00225	CbGeAlD
Sirolimus—ABCB1—lymph node—ovarian cancer	9.44e-05	0.00163	CbGeAlD
Sirolimus—Pancreatitis—Doxorubicin—ovarian cancer	5.91e-05	0.000428	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	5.9e-05	0.000427	CcSEcCtD
Sirolimus—Weight decreased—Epirubicin—ovarian cancer	5.89e-05	0.000426	CcSEcCtD
Sirolimus—Hyperglycaemia—Epirubicin—ovarian cancer	5.87e-05	0.000425	CcSEcCtD
Sirolimus—Cough—Docetaxel—ovarian cancer	5.87e-05	0.000425	CcSEcCtD
Sirolimus—Insomnia—Paclitaxel—ovarian cancer	5.86e-05	0.000424	CcSEcCtD
Sirolimus—Pneumonia—Epirubicin—ovarian cancer	5.84e-05	0.000423	CcSEcCtD
Sirolimus—Paraesthesia—Paclitaxel—ovarian cancer	5.82e-05	0.000421	CcSEcCtD
Sirolimus—Hypertension—Docetaxel—ovarian cancer	5.81e-05	0.00042	CcSEcCtD
Sirolimus—Infestation NOS—Epirubicin—ovarian cancer	5.81e-05	0.00042	CcSEcCtD
Sirolimus—Infestation—Epirubicin—ovarian cancer	5.81e-05	0.00042	CcSEcCtD
Sirolimus—Bronchitis—Doxorubicin—ovarian cancer	5.8e-05	0.000419	CcSEcCtD
Sirolimus—Dyspnoea—Paclitaxel—ovarian cancer	5.78e-05	0.000418	CcSEcCtD
Sirolimus—Somnolence—Paclitaxel—ovarian cancer	5.76e-05	0.000417	CcSEcCtD
Sirolimus—Chest pain—Docetaxel—ovarian cancer	5.73e-05	0.000414	CcSEcCtD
Sirolimus—Myalgia—Docetaxel—ovarian cancer	5.73e-05	0.000414	CcSEcCtD
Sirolimus—Arthralgia—Docetaxel—ovarian cancer	5.73e-05	0.000414	CcSEcCtD
Sirolimus—Pancytopenia—Doxorubicin—ovarian cancer	5.72e-05	0.000414	CcSEcCtD
Sirolimus—Nausea—Vinorelbine—ovarian cancer	5.72e-05	0.000414	CcSEcCtD
Sirolimus—Dyspepsia—Paclitaxel—ovarian cancer	5.7e-05	0.000413	CcSEcCtD
Sirolimus—Neuropathy peripheral—Epirubicin—ovarian cancer	5.69e-05	0.000412	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	5.69e-05	0.000412	CcSEcCtD
Sirolimus—Stomatitis—Epirubicin—ovarian cancer	5.66e-05	0.00041	CcSEcCtD
Sirolimus—Conjunctivitis—Epirubicin—ovarian cancer	5.64e-05	0.000408	CcSEcCtD
Sirolimus—Urinary tract infection—Epirubicin—ovarian cancer	5.64e-05	0.000408	CcSEcCtD
Sirolimus—Dysuria—Doxorubicin—ovarian cancer	5.63e-05	0.000408	CcSEcCtD
Sirolimus—Neutropenia—Doxorubicin—ovarian cancer	5.63e-05	0.000408	CcSEcCtD
Sirolimus—Decreased appetite—Paclitaxel—ovarian cancer	5.63e-05	0.000407	CcSEcCtD
Sirolimus—Upper respiratory tract infection—Doxorubicin—ovarian cancer	5.6e-05	0.000405	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Paclitaxel—ovarian cancer	5.59e-05	0.000405	CcSEcCtD
Sirolimus—Sweating—Epirubicin—ovarian cancer	5.57e-05	0.000403	CcSEcCtD
Sirolimus—Pollakiuria—Doxorubicin—ovarian cancer	5.57e-05	0.000403	CcSEcCtD
Sirolimus—Constipation—Paclitaxel—ovarian cancer	5.54e-05	0.000401	CcSEcCtD
Sirolimus—Pain—Paclitaxel—ovarian cancer	5.54e-05	0.000401	CcSEcCtD
Sirolimus—Haematuria—Epirubicin—ovarian cancer	5.54e-05	0.000401	CcSEcCtD
Sirolimus—Confusional state—Docetaxel—ovarian cancer	5.54e-05	0.000401	CcSEcCtD
Sirolimus—Hepatobiliary disease—Epirubicin—ovarian cancer	5.49e-05	0.000397	CcSEcCtD
Sirolimus—Anaphylactic shock—Docetaxel—ovarian cancer	5.49e-05	0.000397	CcSEcCtD
Sirolimus—Oedema—Docetaxel—ovarian cancer	5.49e-05	0.000397	CcSEcCtD
Sirolimus—Weight increased—Doxorubicin—ovarian cancer	5.48e-05	0.000397	CcSEcCtD
Sirolimus—Epistaxis—Epirubicin—ovarian cancer	5.48e-05	0.000396	CcSEcCtD
Sirolimus—Infection—Docetaxel—ovarian cancer	5.45e-05	0.000395	CcSEcCtD
Sirolimus—Weight decreased—Doxorubicin—ovarian cancer	5.45e-05	0.000394	CcSEcCtD
Sirolimus—Sinusitis—Epirubicin—ovarian cancer	5.45e-05	0.000394	CcSEcCtD
Sirolimus—Hyperglycaemia—Doxorubicin—ovarian cancer	5.44e-05	0.000393	CcSEcCtD
Sirolimus—Pneumonia—Doxorubicin—ovarian cancer	5.4e-05	0.000391	CcSEcCtD
Sirolimus—Shock—Docetaxel—ovarian cancer	5.4e-05	0.000391	CcSEcCtD
Sirolimus—Nervous system disorder—Docetaxel—ovarian cancer	5.38e-05	0.00039	CcSEcCtD
Sirolimus—Thrombocytopenia—Docetaxel—ovarian cancer	5.38e-05	0.000389	CcSEcCtD
Sirolimus—Infestation NOS—Doxorubicin—ovarian cancer	5.37e-05	0.000389	CcSEcCtD
Sirolimus—Infestation—Doxorubicin—ovarian cancer	5.37e-05	0.000389	CcSEcCtD
Sirolimus—Tachycardia—Docetaxel—ovarian cancer	5.36e-05	0.000388	CcSEcCtD
Sirolimus—Feeling abnormal—Paclitaxel—ovarian cancer	5.34e-05	0.000386	CcSEcCtD
Sirolimus—Skin disorder—Docetaxel—ovarian cancer	5.33e-05	0.000386	CcSEcCtD
Sirolimus—Gastrointestinal pain—Paclitaxel—ovarian cancer	5.3e-05	0.000383	CcSEcCtD
Sirolimus—Neuropathy peripheral—Doxorubicin—ovarian cancer	5.27e-05	0.000381	CcSEcCtD
Sirolimus—Haemoglobin—Epirubicin—ovarian cancer	5.24e-05	0.000379	CcSEcCtD
Sirolimus—Stomatitis—Doxorubicin—ovarian cancer	5.24e-05	0.000379	CcSEcCtD
Sirolimus—Anorexia—Docetaxel—ovarian cancer	5.23e-05	0.000379	CcSEcCtD
Sirolimus—Rhinitis—Epirubicin—ovarian cancer	5.23e-05	0.000378	CcSEcCtD
Sirolimus—Conjunctivitis—Doxorubicin—ovarian cancer	5.22e-05	0.000378	CcSEcCtD
Sirolimus—Urinary tract infection—Doxorubicin—ovarian cancer	5.22e-05	0.000378	CcSEcCtD
Sirolimus—Haemorrhage—Epirubicin—ovarian cancer	5.21e-05	0.000377	CcSEcCtD
Sirolimus—Hypoaesthesia—Epirubicin—ovarian cancer	5.19e-05	0.000375	CcSEcCtD
Sirolimus—Pharyngitis—Epirubicin—ovarian cancer	5.17e-05	0.000374	CcSEcCtD
Sirolimus—Sweating—Doxorubicin—ovarian cancer	5.15e-05	0.000373	CcSEcCtD
Sirolimus—Urinary tract disorder—Epirubicin—ovarian cancer	5.15e-05	0.000373	CcSEcCtD
Sirolimus—Oedema peripheral—Epirubicin—ovarian cancer	5.14e-05	0.000372	CcSEcCtD
Sirolimus—Hypotension—Docetaxel—ovarian cancer	5.13e-05	0.000371	CcSEcCtD
Sirolimus—Haematuria—Doxorubicin—ovarian cancer	5.12e-05	0.000371	CcSEcCtD
Sirolimus—Connective tissue disorder—Epirubicin—ovarian cancer	5.12e-05	0.000371	CcSEcCtD
Sirolimus—Abdominal pain—Paclitaxel—ovarian cancer	5.12e-05	0.000371	CcSEcCtD
Sirolimus—Body temperature increased—Paclitaxel—ovarian cancer	5.12e-05	0.000371	CcSEcCtD
Sirolimus—Urethral disorder—Epirubicin—ovarian cancer	5.11e-05	0.00037	CcSEcCtD
Sirolimus—Hepatobiliary disease—Doxorubicin—ovarian cancer	5.08e-05	0.000368	CcSEcCtD
Sirolimus—Epistaxis—Doxorubicin—ovarian cancer	5.07e-05	0.000367	CcSEcCtD
Sirolimus—Sinusitis—Doxorubicin—ovarian cancer	5.04e-05	0.000365	CcSEcCtD
Sirolimus—Visual impairment—Epirubicin—ovarian cancer	5.02e-05	0.000364	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Docetaxel—ovarian cancer	5e-05	0.000362	CcSEcCtD
Sirolimus—Insomnia—Docetaxel—ovarian cancer	4.97e-05	0.000359	CcSEcCtD
Sirolimus—Paraesthesia—Docetaxel—ovarian cancer	4.93e-05	0.000357	CcSEcCtD
Sirolimus—Dyspnoea—Docetaxel—ovarian cancer	4.9e-05	0.000354	CcSEcCtD
Sirolimus—Somnolence—Docetaxel—ovarian cancer	4.88e-05	0.000353	CcSEcCtD
Sirolimus—Tinnitus—Epirubicin—ovarian cancer	4.86e-05	0.000352	CcSEcCtD
Sirolimus—Haemoglobin—Doxorubicin—ovarian cancer	4.85e-05	0.000351	CcSEcCtD
Sirolimus—Cardiac disorder—Epirubicin—ovarian cancer	4.84e-05	0.00035	CcSEcCtD
Sirolimus—Rhinitis—Doxorubicin—ovarian cancer	4.84e-05	0.00035	CcSEcCtD
Sirolimus—Dyspepsia—Docetaxel—ovarian cancer	4.83e-05	0.00035	CcSEcCtD
Sirolimus—Haemorrhage—Doxorubicin—ovarian cancer	4.82e-05	0.000349	CcSEcCtD
Sirolimus—Hypoaesthesia—Doxorubicin—ovarian cancer	4.8e-05	0.000347	CcSEcCtD
Sirolimus—Pharyngitis—Doxorubicin—ovarian cancer	4.79e-05	0.000346	CcSEcCtD
Sirolimus—Decreased appetite—Docetaxel—ovarian cancer	4.77e-05	0.000345	CcSEcCtD
Sirolimus—Hypersensitivity—Paclitaxel—ovarian cancer	4.77e-05	0.000345	CcSEcCtD
Sirolimus—Urinary tract disorder—Doxorubicin—ovarian cancer	4.76e-05	0.000345	CcSEcCtD
Sirolimus—Oedema peripheral—Doxorubicin—ovarian cancer	4.75e-05	0.000344	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Docetaxel—ovarian cancer	4.74e-05	0.000343	CcSEcCtD
Sirolimus—Connective tissue disorder—Doxorubicin—ovarian cancer	4.74e-05	0.000343	CcSEcCtD
Sirolimus—Angiopathy—Epirubicin—ovarian cancer	4.73e-05	0.000342	CcSEcCtD
Sirolimus—Urethral disorder—Doxorubicin—ovarian cancer	4.73e-05	0.000342	CcSEcCtD
Sirolimus—Immune system disorder—Epirubicin—ovarian cancer	4.71e-05	0.000341	CcSEcCtD
Sirolimus—Mediastinal disorder—Epirubicin—ovarian cancer	4.7e-05	0.00034	CcSEcCtD
Sirolimus—Pain—Docetaxel—ovarian cancer	4.7e-05	0.00034	CcSEcCtD
Sirolimus—Constipation—Docetaxel—ovarian cancer	4.7e-05	0.00034	CcSEcCtD
Sirolimus—Chills—Epirubicin—ovarian cancer	4.68e-05	0.000338	CcSEcCtD
Sirolimus—Visual impairment—Doxorubicin—ovarian cancer	4.65e-05	0.000336	CcSEcCtD
Sirolimus—Asthenia—Paclitaxel—ovarian cancer	4.65e-05	0.000336	CcSEcCtD
Sirolimus—Pruritus—Paclitaxel—ovarian cancer	4.58e-05	0.000332	CcSEcCtD
Sirolimus—Malnutrition—Epirubicin—ovarian cancer	4.54e-05	0.000328	CcSEcCtD
Sirolimus—Feeling abnormal—Docetaxel—ovarian cancer	4.52e-05	0.000327	CcSEcCtD
Sirolimus—Tinnitus—Doxorubicin—ovarian cancer	4.5e-05	0.000325	CcSEcCtD
Sirolimus—Gastrointestinal pain—Docetaxel—ovarian cancer	4.49e-05	0.000325	CcSEcCtD
Sirolimus—Cardiac disorder—Doxorubicin—ovarian cancer	4.48e-05	0.000324	CcSEcCtD
Sirolimus—Flatulence—Epirubicin—ovarian cancer	4.47e-05	0.000324	CcSEcCtD
Sirolimus—Tension—Epirubicin—ovarian cancer	4.45e-05	0.000322	CcSEcCtD
Sirolimus—Diarrhoea—Paclitaxel—ovarian cancer	4.43e-05	0.000321	CcSEcCtD
Sirolimus—Nervousness—Epirubicin—ovarian cancer	4.41e-05	0.000319	CcSEcCtD
Sirolimus—Back pain—Epirubicin—ovarian cancer	4.39e-05	0.000318	CcSEcCtD
Sirolimus—Angiopathy—Doxorubicin—ovarian cancer	4.38e-05	0.000317	CcSEcCtD
Sirolimus—Muscle spasms—Epirubicin—ovarian cancer	4.36e-05	0.000316	CcSEcCtD
Sirolimus—Immune system disorder—Doxorubicin—ovarian cancer	4.36e-05	0.000315	CcSEcCtD
Sirolimus—Mediastinal disorder—Doxorubicin—ovarian cancer	4.35e-05	0.000315	CcSEcCtD
Sirolimus—Abdominal pain—Docetaxel—ovarian cancer	4.34e-05	0.000314	CcSEcCtD
Sirolimus—Body temperature increased—Docetaxel—ovarian cancer	4.34e-05	0.000314	CcSEcCtD
Sirolimus—Chills—Doxorubicin—ovarian cancer	4.33e-05	0.000313	CcSEcCtD
Sirolimus—Dizziness—Paclitaxel—ovarian cancer	4.28e-05	0.00031	CcSEcCtD
Sirolimus—Ill-defined disorder—Epirubicin—ovarian cancer	4.21e-05	0.000305	CcSEcCtD
Sirolimus—Malnutrition—Doxorubicin—ovarian cancer	4.2e-05	0.000304	CcSEcCtD
Sirolimus—Anaemia—Epirubicin—ovarian cancer	4.19e-05	0.000303	CcSEcCtD
Sirolimus—Agitation—Epirubicin—ovarian cancer	4.17e-05	0.000302	CcSEcCtD
Sirolimus—Flatulence—Doxorubicin—ovarian cancer	4.14e-05	0.000299	CcSEcCtD
Sirolimus—Tension—Doxorubicin—ovarian cancer	4.12e-05	0.000298	CcSEcCtD
Sirolimus—Vomiting—Paclitaxel—ovarian cancer	4.12e-05	0.000298	CcSEcCtD
Sirolimus—Malaise—Epirubicin—ovarian cancer	4.09e-05	0.000296	CcSEcCtD
Sirolimus—Rash—Paclitaxel—ovarian cancer	4.08e-05	0.000296	CcSEcCtD
Sirolimus—Dermatitis—Paclitaxel—ovarian cancer	4.08e-05	0.000295	CcSEcCtD
Sirolimus—Nervousness—Doxorubicin—ovarian cancer	4.08e-05	0.000295	CcSEcCtD
Sirolimus—Syncope—Epirubicin—ovarian cancer	4.07e-05	0.000294	CcSEcCtD
Sirolimus—Leukopenia—Epirubicin—ovarian cancer	4.06e-05	0.000294	CcSEcCtD
Sirolimus—Back pain—Doxorubicin—ovarian cancer	4.06e-05	0.000294	CcSEcCtD
Sirolimus—Headache—Paclitaxel—ovarian cancer	4.06e-05	0.000294	CcSEcCtD
Sirolimus—Hypersensitivity—Docetaxel—ovarian cancer	4.05e-05	0.000293	CcSEcCtD
Sirolimus—Muscle spasms—Doxorubicin—ovarian cancer	4.04e-05	0.000292	CcSEcCtD
Sirolimus—Palpitations—Epirubicin—ovarian cancer	4.01e-05	0.00029	CcSEcCtD
Sirolimus—Loss of consciousness—Epirubicin—ovarian cancer	3.99e-05	0.000289	CcSEcCtD
Sirolimus—Cough—Epirubicin—ovarian cancer	3.96e-05	0.000287	CcSEcCtD
Sirolimus—Asthenia—Docetaxel—ovarian cancer	3.94e-05	0.000285	CcSEcCtD
Sirolimus—Hypertension—Epirubicin—ovarian cancer	3.92e-05	0.000283	CcSEcCtD
Sirolimus—Ill-defined disorder—Doxorubicin—ovarian cancer	3.9e-05	0.000282	CcSEcCtD
Sirolimus—Pruritus—Docetaxel—ovarian cancer	3.88e-05	0.000281	CcSEcCtD
Sirolimus—Anaemia—Doxorubicin—ovarian cancer	3.88e-05	0.000281	CcSEcCtD
Sirolimus—Arthralgia—Epirubicin—ovarian cancer	3.86e-05	0.00028	CcSEcCtD
Sirolimus—Chest pain—Epirubicin—ovarian cancer	3.86e-05	0.00028	CcSEcCtD
Sirolimus—Myalgia—Epirubicin—ovarian cancer	3.86e-05	0.00028	CcSEcCtD
Sirolimus—Agitation—Doxorubicin—ovarian cancer	3.86e-05	0.000279	CcSEcCtD
Sirolimus—Anxiety—Epirubicin—ovarian cancer	3.85e-05	0.000279	CcSEcCtD
Sirolimus—Nausea—Paclitaxel—ovarian cancer	3.85e-05	0.000278	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	3.84e-05	0.000278	CcSEcCtD
Sirolimus—Discomfort—Epirubicin—ovarian cancer	3.82e-05	0.000276	CcSEcCtD
Sirolimus—Malaise—Doxorubicin—ovarian cancer	3.79e-05	0.000274	CcSEcCtD
Sirolimus—Syncope—Doxorubicin—ovarian cancer	3.77e-05	0.000272	CcSEcCtD
Sirolimus—Leukopenia—Doxorubicin—ovarian cancer	3.76e-05	0.000272	CcSEcCtD
Sirolimus—Diarrhoea—Docetaxel—ovarian cancer	3.76e-05	0.000272	CcSEcCtD
Sirolimus—Confusional state—Epirubicin—ovarian cancer	3.73e-05	0.00027	CcSEcCtD
Sirolimus—Palpitations—Doxorubicin—ovarian cancer	3.71e-05	0.000268	CcSEcCtD
Sirolimus—Anaphylactic shock—Epirubicin—ovarian cancer	3.7e-05	0.000268	CcSEcCtD
Sirolimus—Oedema—Epirubicin—ovarian cancer	3.7e-05	0.000268	CcSEcCtD
Sirolimus—Loss of consciousness—Doxorubicin—ovarian cancer	3.69e-05	0.000267	CcSEcCtD
Sirolimus—Infection—Epirubicin—ovarian cancer	3.68e-05	0.000266	CcSEcCtD
Sirolimus—Cough—Doxorubicin—ovarian cancer	3.66e-05	0.000265	CcSEcCtD
Sirolimus—Shock—Epirubicin—ovarian cancer	3.64e-05	0.000264	CcSEcCtD
Sirolimus—Nervous system disorder—Epirubicin—ovarian cancer	3.63e-05	0.000263	CcSEcCtD
Sirolimus—Dizziness—Docetaxel—ovarian cancer	3.63e-05	0.000263	CcSEcCtD
Sirolimus—Thrombocytopenia—Epirubicin—ovarian cancer	3.63e-05	0.000262	CcSEcCtD
Sirolimus—Hypertension—Doxorubicin—ovarian cancer	3.63e-05	0.000262	CcSEcCtD
Sirolimus—Tachycardia—Epirubicin—ovarian cancer	3.61e-05	0.000262	CcSEcCtD
Sirolimus—Skin disorder—Epirubicin—ovarian cancer	3.6e-05	0.00026	CcSEcCtD
Sirolimus—Hyperhidrosis—Epirubicin—ovarian cancer	3.58e-05	0.000259	CcSEcCtD
Sirolimus—Arthralgia—Doxorubicin—ovarian cancer	3.57e-05	0.000259	CcSEcCtD
Sirolimus—Chest pain—Doxorubicin—ovarian cancer	3.57e-05	0.000259	CcSEcCtD
Sirolimus—Myalgia—Doxorubicin—ovarian cancer	3.57e-05	0.000259	CcSEcCtD
Sirolimus—Anxiety—Doxorubicin—ovarian cancer	3.56e-05	0.000258	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	3.55e-05	0.000257	CcSEcCtD
Sirolimus—Discomfort—Doxorubicin—ovarian cancer	3.53e-05	0.000256	CcSEcCtD
Sirolimus—Anorexia—Epirubicin—ovarian cancer	3.53e-05	0.000255	CcSEcCtD
Sirolimus—Vomiting—Docetaxel—ovarian cancer	3.49e-05	0.000253	CcSEcCtD
Sirolimus—Rash—Docetaxel—ovarian cancer	3.46e-05	0.000251	CcSEcCtD
Sirolimus—Hypotension—Epirubicin—ovarian cancer	3.46e-05	0.00025	CcSEcCtD
Sirolimus—Dermatitis—Docetaxel—ovarian cancer	3.46e-05	0.00025	CcSEcCtD
Sirolimus—Confusional state—Doxorubicin—ovarian cancer	3.46e-05	0.00025	CcSEcCtD
Sirolimus—Headache—Docetaxel—ovarian cancer	3.44e-05	0.000249	CcSEcCtD
Sirolimus—Anaphylactic shock—Doxorubicin—ovarian cancer	3.43e-05	0.000248	CcSEcCtD
Sirolimus—Oedema—Doxorubicin—ovarian cancer	3.43e-05	0.000248	CcSEcCtD
Sirolimus—Infection—Doxorubicin—ovarian cancer	3.4e-05	0.000246	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Epirubicin—ovarian cancer	3.37e-05	0.000244	CcSEcCtD
Sirolimus—Shock—Doxorubicin—ovarian cancer	3.37e-05	0.000244	CcSEcCtD
Sirolimus—Nervous system disorder—Doxorubicin—ovarian cancer	3.36e-05	0.000243	CcSEcCtD
Sirolimus—Thrombocytopenia—Doxorubicin—ovarian cancer	3.36e-05	0.000243	CcSEcCtD
Sirolimus—Insomnia—Epirubicin—ovarian cancer	3.35e-05	0.000242	CcSEcCtD
Sirolimus—Tachycardia—Doxorubicin—ovarian cancer	3.34e-05	0.000242	CcSEcCtD
Sirolimus—Skin disorder—Doxorubicin—ovarian cancer	3.33e-05	0.000241	CcSEcCtD
Sirolimus—Paraesthesia—Epirubicin—ovarian cancer	3.33e-05	0.000241	CcSEcCtD
Sirolimus—Hyperhidrosis—Doxorubicin—ovarian cancer	3.31e-05	0.00024	CcSEcCtD
Sirolimus—Dyspnoea—Epirubicin—ovarian cancer	3.3e-05	0.000239	CcSEcCtD
Sirolimus—Somnolence—Epirubicin—ovarian cancer	3.29e-05	0.000238	CcSEcCtD
Sirolimus—Anorexia—Doxorubicin—ovarian cancer	3.27e-05	0.000236	CcSEcCtD
Sirolimus—Nausea—Docetaxel—ovarian cancer	3.26e-05	0.000236	CcSEcCtD
Sirolimus—Dyspepsia—Epirubicin—ovarian cancer	3.26e-05	0.000236	CcSEcCtD
Sirolimus—Decreased appetite—Epirubicin—ovarian cancer	3.22e-05	0.000233	CcSEcCtD
Sirolimus—Hypotension—Doxorubicin—ovarian cancer	3.2e-05	0.000232	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Epirubicin—ovarian cancer	3.2e-05	0.000231	CcSEcCtD
Sirolimus—Pain—Epirubicin—ovarian cancer	3.17e-05	0.000229	CcSEcCtD
Sirolimus—Constipation—Epirubicin—ovarian cancer	3.17e-05	0.000229	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	3.12e-05	0.000226	CcSEcCtD
Sirolimus—Insomnia—Doxorubicin—ovarian cancer	3.1e-05	0.000224	CcSEcCtD
Sirolimus—Paraesthesia—Doxorubicin—ovarian cancer	3.08e-05	0.000223	CcSEcCtD
Sirolimus—Dyspnoea—Doxorubicin—ovarian cancer	3.06e-05	0.000221	CcSEcCtD
Sirolimus—Feeling abnormal—Epirubicin—ovarian cancer	3.05e-05	0.000221	CcSEcCtD
Sirolimus—Somnolence—Doxorubicin—ovarian cancer	3.05e-05	0.00022	CcSEcCtD
Sirolimus—Gastrointestinal pain—Epirubicin—ovarian cancer	3.03e-05	0.000219	CcSEcCtD
Sirolimus—Dyspepsia—Doxorubicin—ovarian cancer	3.02e-05	0.000218	CcSEcCtD
Sirolimus—Decreased appetite—Doxorubicin—ovarian cancer	2.98e-05	0.000216	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Doxorubicin—ovarian cancer	2.96e-05	0.000214	CcSEcCtD
Sirolimus—Pain—Doxorubicin—ovarian cancer	2.93e-05	0.000212	CcSEcCtD
Sirolimus—Constipation—Doxorubicin—ovarian cancer	2.93e-05	0.000212	CcSEcCtD
Sirolimus—Abdominal pain—Epirubicin—ovarian cancer	2.93e-05	0.000212	CcSEcCtD
Sirolimus—Body temperature increased—Epirubicin—ovarian cancer	2.93e-05	0.000212	CcSEcCtD
Sirolimus—Feeling abnormal—Doxorubicin—ovarian cancer	2.82e-05	0.000204	CcSEcCtD
Sirolimus—Gastrointestinal pain—Doxorubicin—ovarian cancer	2.8e-05	0.000203	CcSEcCtD
Sirolimus—Hypersensitivity—Epirubicin—ovarian cancer	2.73e-05	0.000197	CcSEcCtD
Sirolimus—Abdominal pain—Doxorubicin—ovarian cancer	2.71e-05	0.000196	CcSEcCtD
Sirolimus—Body temperature increased—Doxorubicin—ovarian cancer	2.71e-05	0.000196	CcSEcCtD
Sirolimus—Asthenia—Epirubicin—ovarian cancer	2.66e-05	0.000192	CcSEcCtD
Sirolimus—Pruritus—Epirubicin—ovarian cancer	2.62e-05	0.00019	CcSEcCtD
Sirolimus—Diarrhoea—Epirubicin—ovarian cancer	2.53e-05	0.000183	CcSEcCtD
Sirolimus—Hypersensitivity—Doxorubicin—ovarian cancer	2.52e-05	0.000183	CcSEcCtD
Sirolimus—Asthenia—Doxorubicin—ovarian cancer	2.46e-05	0.000178	CcSEcCtD
Sirolimus—Dizziness—Epirubicin—ovarian cancer	2.45e-05	0.000177	CcSEcCtD
Sirolimus—Pruritus—Doxorubicin—ovarian cancer	2.42e-05	0.000175	CcSEcCtD
Sirolimus—Vomiting—Epirubicin—ovarian cancer	2.35e-05	0.00017	CcSEcCtD
Sirolimus—Diarrhoea—Doxorubicin—ovarian cancer	2.34e-05	0.00017	CcSEcCtD
Sirolimus—Rash—Epirubicin—ovarian cancer	2.34e-05	0.000169	CcSEcCtD
Sirolimus—Dermatitis—Epirubicin—ovarian cancer	2.33e-05	0.000169	CcSEcCtD
Sirolimus—Headache—Epirubicin—ovarian cancer	2.32e-05	0.000168	CcSEcCtD
Sirolimus—Dizziness—Doxorubicin—ovarian cancer	2.27e-05	0.000164	CcSEcCtD
Sirolimus—Nausea—Epirubicin—ovarian cancer	2.2e-05	0.000159	CcSEcCtD
Sirolimus—Vomiting—Doxorubicin—ovarian cancer	2.18e-05	0.000158	CcSEcCtD
Sirolimus—Rash—Doxorubicin—ovarian cancer	2.16e-05	0.000156	CcSEcCtD
Sirolimus—Dermatitis—Doxorubicin—ovarian cancer	2.16e-05	0.000156	CcSEcCtD
Sirolimus—Headache—Doxorubicin—ovarian cancer	2.15e-05	0.000155	CcSEcCtD
Sirolimus—Nausea—Doxorubicin—ovarian cancer	2.04e-05	0.000147	CcSEcCtD
Sirolimus—EIF4E—Signaling Pathways—NRAS—ovarian cancer	7.43e-06	6.64e-05	CbGpPWpGaD
Sirolimus—EIF4E—Immune System—AKT1—ovarian cancer	7.43e-06	6.64e-05	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—MAPK1—ovarian cancer	7.42e-06	6.63e-05	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—EGFR—ovarian cancer	7.42e-06	6.63e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—APC—ovarian cancer	7.41e-06	6.62e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—ABCB1—ovarian cancer	7.41e-06	6.62e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—ESR1—ovarian cancer	7.4e-06	6.61e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CDH1—ovarian cancer	7.39e-06	6.6e-05	CbGpPWpGaD
Sirolimus—EIF4E—Gene Expression—AKT1—ovarian cancer	7.39e-06	6.6e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—CTNNB1—ovarian cancer	7.35e-06	6.57e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PPP2R1A—ovarian cancer	7.32e-06	6.54e-05	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—ovarian cancer	7.31e-06	6.53e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—IL6ST—ovarian cancer	7.28e-06	6.5e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—TYMS—ovarian cancer	7.28e-06	6.5e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—MYC—ovarian cancer	7.25e-06	6.48e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—CDKN1B—ovarian cancer	7.18e-06	6.42e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—ERBB2—ovarian cancer	7.17e-06	6.4e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—PTEN—ovarian cancer	7.17e-06	6.4e-05	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—EGFR—ovarian cancer	7.13e-06	6.37e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—MAPK3—ovarian cancer	7.12e-06	6.36e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—MAPK1—ovarian cancer	7.1e-06	6.34e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—EGFR—ovarian cancer	7.1e-06	6.34e-05	CbGpPWpGaD
Sirolimus—FGF2—Innate Immune System—AKT1—ovarian cancer	7.09e-06	6.33e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—MTOR—ovarian cancer	7.07e-06	6.32e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—PIK3CB—ovarian cancer	7.07e-06	6.32e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—PIK3CD—ovarian cancer	7.06e-06	6.31e-05	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—KRAS—ovarian cancer	7.01e-06	6.26e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—PIK3CG—ovarian cancer	7e-06	6.25e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—APC—ovarian cancer	7e-06	6.25e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—MYC—ovarian cancer	6.93e-06	6.19e-05	CbGpPWpGaD
Sirolimus—FGF2—Adaptive Immune System—AKT1—ovarian cancer	6.81e-06	6.08e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—ABCB1—ovarian cancer	6.8e-06	6.07e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CXCL8—ovarian cancer	6.8e-06	6.07e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—CTNNB1—ovarian cancer	6.79e-06	6.06e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—MAPK1—ovarian cancer	6.78e-06	6.05e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—EGFR—ovarian cancer	6.77e-06	6.05e-05	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—KRAS—ovarian cancer	6.73e-06	6.01e-05	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	6.71e-06	6e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—KRAS—ovarian cancer	6.7e-06	5.99e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—TYMS—ovarian cancer	6.68e-06	5.96e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CDKN1B—ovarian cancer	6.64e-06	5.93e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—PTEN—ovarian cancer	6.62e-06	5.91e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—FASN—ovarian cancer	6.55e-06	5.85e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—PIK3CD—ovarian cancer	6.52e-06	5.82e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CASP3—ovarian cancer	6.51e-06	5.81e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—IL2—ovarian cancer	6.5e-06	5.8e-05	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	6.5e-06	5.8e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—SLC5A5—ovarian cancer	6.45e-06	5.76e-05	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—PIK3CA—ovarian cancer	6.44e-06	5.75e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—STAT3—ovarian cancer	6.41e-06	5.72e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—KRAS—ovarian cancer	6.4e-06	5.72e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—NRAS—ovarian cancer	6.39e-06	5.71e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CYTB—ovarian cancer	6.37e-06	5.69e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CCND1—ovarian cancer	6.33e-06	5.66e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—CTNNB1—ovarian cancer	6.27e-06	5.6e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—ERBB2—ovarian cancer	6.24e-06	5.57e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—SLC2A1—ovarian cancer	6.22e-06	5.56e-05	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—PIK3CA—ovarian cancer	6.18e-06	5.52e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TERT—ovarian cancer	6.16e-06	5.5e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—PIK3CA—ovarian cancer	6.16e-06	5.5e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—PIK3CB—ovarian cancer	6.15e-06	5.5e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—PIK3CD—ovarian cancer	6.15e-06	5.49e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—MMP9—ovarian cancer	6.15e-06	5.49e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—MAPK3—ovarian cancer	6.12e-06	5.47e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—PTEN—ovarian cancer	6.11e-06	5.46e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—YAP1—ovarian cancer	6.07e-06	5.42e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—CYP1B1—ovarian cancer	5.97e-06	5.33e-05	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—HRAS—ovarian cancer	5.96e-06	5.32e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—STAT3—ovarian cancer	5.92e-06	5.28e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—NRAS—ovarian cancer	5.9e-06	5.27e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—PIK3CA—ovarian cancer	5.88e-06	5.25e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—CAV1—ovarian cancer	5.86e-06	5.24e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—MAPK1—ovarian cancer	5.83e-06	5.2e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—EGFR—ovarian cancer	5.82e-06	5.2e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CDKN1B—ovarian cancer	5.77e-06	5.16e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—ERBB2—ovarian cancer	5.76e-06	5.14e-05	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—HRAS—ovarian cancer	5.72e-06	5.11e-05	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—IL6—ovarian cancer	5.7e-06	5.09e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CAV1—ovarian cancer	5.7e-06	5.09e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—HRAS—ovarian cancer	5.7e-06	5.09e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—TP53—ovarian cancer	5.69e-06	5.08e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—PIK3CB—ovarian cancer	5.68e-06	5.07e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—MAPK3—ovarian cancer	5.65e-06	5.05e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—IL2—ovarian cancer	5.65e-06	5.05e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	5.6e-06	5e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PPP1CC—ovarian cancer	5.57e-06	4.98e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—BRIP1—ovarian cancer	5.57e-06	4.98e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—VEGFA—ovarian cancer	5.52e-06	4.93e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—KRAS—ovarian cancer	5.5e-06	4.91e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—MYC—ovarian cancer	5.5e-06	4.91e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—ESR1—ovarian cancer	5.49e-06	4.91e-05	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	5.49e-06	4.9e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—STAT3—ovarian cancer	5.47e-06	4.88e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CTNNB1—ovarian cancer	5.46e-06	4.87e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—NRAS—ovarian cancer	5.45e-06	4.87e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—IL6—ovarian cancer	5.45e-06	4.87e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—HRAS—ovarian cancer	5.44e-06	4.86e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—ERBB2—ovarian cancer	5.43e-06	4.85e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—IL6ST—ovarian cancer	5.4e-06	4.83e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—CAV1—ovarian cancer	5.38e-06	4.81e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—MAPK1—ovarian cancer	5.38e-06	4.8e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—EGFR—ovarian cancer	5.38e-06	4.8e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MTOR—ovarian cancer	5.36e-06	4.79e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—PIK3CB—ovarian cancer	5.36e-06	4.79e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PIK3CG—ovarian cancer	5.34e-06	4.77e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—CDKN1B—ovarian cancer	5.33e-06	4.76e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—PTEN—ovarian cancer	5.32e-06	4.75e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PPP2R1A—ovarian cancer	5.29e-06	4.73e-05	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—AKT1—ovarian cancer	5.26e-06	4.7e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—MAPK3—ovarian cancer	5.22e-06	4.67e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—IL6—ovarian cancer	5.21e-06	4.65e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—APC—ovarian cancer	5.19e-06	4.64e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PIK3CG—ovarian cancer	5.19e-06	4.64e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CXCL8—ovarian cancer	5.15e-06	4.6e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—MYC—ovarian cancer	5.08e-06	4.54e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—KRAS—ovarian cancer	5.08e-06	4.54e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—PIK3CA—ovarian cancer	5.05e-06	4.52e-05	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—AKT1—ovarian cancer	5.05e-06	4.51e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—CTNNB1—ovarian cancer	5.04e-06	4.5e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CDKN1B—ovarian cancer	5.03e-06	4.49e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—AKT1—ovarian cancer	5.03e-06	4.49e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—MAPK1—ovarian cancer	4.97e-06	4.44e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—EGFR—ovarian cancer	4.97e-06	4.44e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—FASN—ovarian cancer	4.94e-06	4.42e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CASP3—ovarian cancer	4.93e-06	4.4e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—IL2—ovarian cancer	4.92e-06	4.4e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—ABCB1—ovarian cancer	4.91e-06	4.39e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—PTEN—ovarian cancer	4.91e-06	4.39e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PIK3CG—ovarian cancer	4.9e-06	4.38e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—SLC5A5—ovarian cancer	4.86e-06	4.34e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—TYMS—ovarian cancer	4.83e-06	4.31e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—AKT1—ovarian cancer	4.8e-06	4.29e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CCND1—ovarian cancer	4.8e-06	4.29e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—STAT3—ovarian cancer	4.76e-06	4.25e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CTNNB1—ovarian cancer	4.75e-06	4.25e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—NRAS—ovarian cancer	4.74e-06	4.24e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—SLC2A1—ovarian cancer	4.7e-06	4.2e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PIK3CD—ovarian cancer	4.69e-06	4.19e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—KRAS—ovarian cancer	4.69e-06	4.19e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—HRAS—ovarian cancer	4.68e-06	4.18e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—PIK3CA—ovarian cancer	4.67e-06	4.17e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MMP9—ovarian cancer	4.66e-06	4.16e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—PTEN—ovarian cancer	4.63e-06	4.14e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PIK3CD—ovarian cancer	4.56e-06	4.08e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—MAPK3—ovarian cancer	4.54e-06	4.06e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CYP1B1—ovarian cancer	4.5e-06	4.02e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—IL6—ovarian cancer	4.48e-06	4e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—STAT3—ovarian cancer	4.39e-06	3.92e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—NRAS—ovarian cancer	4.38e-06	3.91e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—MAPK1—ovarian cancer	4.32e-06	3.86e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—EGFR—ovarian cancer	4.32e-06	3.86e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—HRAS—ovarian cancer	4.32e-06	3.86e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—PIK3CA—ovarian cancer	4.31e-06	3.85e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PIK3CD—ovarian cancer	4.31e-06	3.85e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—MAPK3—ovarian cancer	4.19e-06	3.75e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—VEGFA—ovarian cancer	4.18e-06	3.74e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—TP53—ovarian cancer	4.17e-06	3.73e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—STAT3—ovarian cancer	4.14e-06	3.7e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—NRAS—ovarian cancer	4.13e-06	3.69e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—IL6—ovarian cancer	4.13e-06	3.69e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—AKT1—ovarian cancer	4.13e-06	3.69e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PIK3CB—ovarian cancer	4.09e-06	3.65e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—KRAS—ovarian cancer	4.08e-06	3.65e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—MYC—ovarian cancer	4.08e-06	3.64e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—ERBB2—ovarian cancer	4.03e-06	3.6e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PPP2R1A—ovarian cancer	3.99e-06	3.57e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—MAPK1—ovarian cancer	3.99e-06	3.57e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—EGFR—ovarian cancer	3.99e-06	3.56e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—HRAS—ovarian cancer	3.99e-06	3.56e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PIK3CB—ovarian cancer	3.98e-06	3.55e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MAPK3—ovarian cancer	3.96e-06	3.54e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—CAV1—ovarian cancer	3.89e-06	3.47e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MYC—ovarian cancer	3.85e-06	3.44e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CXCL8—ovarian cancer	3.82e-06	3.42e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—IL6—ovarian cancer	3.82e-06	3.41e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—AKT1—ovarian cancer	3.81e-06	3.41e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—KRAS—ovarian cancer	3.77e-06	3.37e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MAPK1—ovarian cancer	3.77e-06	3.36e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—EGFR—ovarian cancer	3.77e-06	3.36e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PIK3CB—ovarian cancer	3.76e-06	3.35e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—PIK3CA—ovarian cancer	3.75e-06	3.35e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—YAP1—ovarian cancer	3.74e-06	3.34e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CDKN1B—ovarian cancer	3.73e-06	3.34e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CASP3—ovarian cancer	3.66e-06	3.27e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—IL2—ovarian cancer	3.65e-06	3.26e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—TYMS—ovarian cancer	3.64e-06	3.25e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CCND1—ovarian cancer	3.56e-06	3.18e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—KRAS—ovarian cancer	3.56e-06	3.18e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PIK3CG—ovarian cancer	3.54e-06	3.16e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PTEN—ovarian cancer	3.54e-06	3.16e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CTNNB1—ovarian cancer	3.53e-06	3.15e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—AKT1—ovarian cancer	3.52e-06	3.15e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—HRAS—ovarian cancer	3.47e-06	3.1e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—PIK3CA—ovarian cancer	3.46e-06	3.09e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—MMP9—ovarian cancer	3.46e-06	3.09e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PTEN—ovarian cancer	3.44e-06	3.07e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—IL6—ovarian cancer	3.32e-06	2.97e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—PIK3CA—ovarian cancer	3.27e-06	2.92e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PTEN—ovarian cancer	3.24e-06	2.9e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—HRAS—ovarian cancer	3.2e-06	2.86e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—TP53—ovarian cancer	3.16e-06	2.82e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PIK3CD—ovarian cancer	3.11e-06	2.78e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—VEGFA—ovarian cancer	3.11e-06	2.77e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—STAT3—ovarian cancer	3.07e-06	2.75e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—NRAS—ovarian cancer	3.07e-06	2.74e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—IL6—ovarian cancer	3.07e-06	2.74e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—AKT1—ovarian cancer	3.06e-06	2.74e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—FASN—ovarian cancer	3.05e-06	2.72e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—HRAS—ovarian cancer	3.02e-06	2.7e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—SLC5A5—ovarian cancer	3e-06	2.68e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—MAPK3—ovarian cancer	2.94e-06	2.62e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CAV1—ovarian cancer	2.93e-06	2.62e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—IL6—ovarian cancer	2.89e-06	2.59e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—SLC2A1—ovarian cancer	2.89e-06	2.59e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—MYC—ovarian cancer	2.86e-06	2.55e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—AKT1—ovarian cancer	2.83e-06	2.53e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—MAPK1—ovarian cancer	2.79e-06	2.5e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—EGFR—ovarian cancer	2.79e-06	2.5e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CYP1B1—ovarian cancer	2.77e-06	2.48e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PIK3CB—ovarian cancer	2.71e-06	2.42e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PIK3CG—ovarian cancer	2.67e-06	2.39e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—AKT1—ovarian cancer	2.67e-06	2.38e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—KRAS—ovarian cancer	2.64e-06	2.36e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PIK3CA—ovarian cancer	2.49e-06	2.23e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	2.46e-06	2.2e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PIK3CA—ovarian cancer	2.43e-06	2.17e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PIK3CD—ovarian cancer	2.35e-06	2.1e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TP53—ovarian cancer	2.35e-06	2.1e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PTEN—ovarian cancer	2.35e-06	2.1e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PIK3CA—ovarian cancer	2.29e-06	2.04e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ABCB1—ovarian cancer	2.28e-06	2.04e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—TYMS—ovarian cancer	2.24e-06	2e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—HRAS—ovarian cancer	2.24e-06	2e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—IL6—ovarian cancer	2.15e-06	1.92e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PIK3CB—ovarian cancer	2.05e-06	1.83e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—AKT1—ovarian cancer	2.04e-06	1.82e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—AKT1—ovarian cancer	1.98e-06	1.77e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—AKT1—ovarian cancer	1.87e-06	1.67e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CAV1—ovarian cancer	1.81e-06	1.62e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PTEN—ovarian cancer	1.77e-06	1.58e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PIK3CA—ovarian cancer	1.65e-06	1.48e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PIK3CG—ovarian cancer	1.65e-06	1.47e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PIK3CD—ovarian cancer	1.45e-06	1.29e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—AKT1—ovarian cancer	1.35e-06	1.21e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PIK3CB—ovarian cancer	1.26e-06	1.13e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PIK3CA—ovarian cancer	1.25e-06	1.12e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PTEN—ovarian cancer	1.09e-06	9.74e-06	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—AKT1—ovarian cancer	1.02e-06	9.11e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PIK3CA—ovarian cancer	7.69e-07	6.87e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—AKT1—ovarian cancer	6.28e-07	5.61e-06	CbGpPWpGaD
